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Assessing the role of Porphyromonas gingivalis in periodontitis to determine a
causative relationship with Alzheimer’s disease
Sim K. Singhraoa and Ingar Olsenb
aDementia and Neurodegenerative Diseases Research Group, Faculty of Clinical and Biomedical Sciences, School of Dentistry, University
of Central Lancashire, Preston, UK; bDepartment of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway
ABSTRACT
Chronic periodontitis of 10 years’ duration is reported to become a twofold risk factor for the
development of Alzheimer’s disease (AD). Periodontitis is modifiable, and this fits with the
current action plan for preventing AD. However, until periodontitis, becomes acknowledged
as a firm risk factor for AD, this risk will continue. Here, we put forward our own argument
based on the current literature for in vivo infection-mediated periodontal disease models
supporting the antimicrobial protection hypothesis of AD and interventional studies support-
ing the causal links. Oral infections with Porphyromonas gingivalis, or introduction of its
lipopolysaccharide (LPS), in various mouse models has demonstrated the development of
key neuropathological hallmark lesions defining AD. These are extracellular amyloid-beta
plaques, phosphorylated tau, neurofibrillary tangles, widespread acute and chronic inflam-
mation, blood–brain barrier defects together with the clinical phenotype showing impaired
learning and spatial memory. Live P. gingivalis and its LPS (commercial or from ‘microbullets’)
are powerful peripheral and intracerebral inflammatory signalling initiators, and this has
direct implications on memory and lesion development. Maintaining a healthy oral micro-
biome and managing periodontal disease with regular surveillance and good oral hygiene
throughout life is likely to reduce the unnecessary burden of AD in some individuals.
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Introduction
Periodontitis is a highly prevalent oral disease in humans
affecting nearly 50% of the population worldwide [1].
The polymicrobial infectious aetiology of chronic period-
ontitis is due to the host’s sub-gingival pathobiome,
which initiates hard/soft tissue destruction that worsens
with advancing age. Furthermore, the dysbiotic oral bio-
film consortia can affect the functioning of the brain,
potentially causing depressive illnesses, as implicated in
the development of dementia [2]. Risk factors for period-
ontal disease are smoking [3], alcohol consumption [4],
and poor oral hygiene [5]. Paganini-Hill et al. [6] high-
lighted that behavioural factors involving oral hygiene
were significant in dementia onset, stating that, dentate
individuals who did not brush their teeth daily, had a
22–65% greater risk of developing dementia compared
with individuals who brushed their teeth three times
daily [6]. These statistics suggest a proportion of indivi-
duals are particularly susceptible to Porphyromonas gin-
givalis infections, because not everyone suffers from
periodontitis and not all who develop Alzheimer’s
dementia suffer from periodontitis [7]. Periodontal dis-
ease is modifiable by both professional intervention and
personal behavioural changes associated with oral
hygiene [8,9], and this offers an avenue for reducing
unnecessary mental health suffering for some individuals
in their old age. In addition, therapeutic elements of
prevention and treatment of dementia with a view to
anti-P. gingivalis therapy are being sought. For example,
Cortexyme Inc®, a USA based company is seeking their
lead compound, COR388; to treat dementia in Phase 1
clinical trials. Such preventive measures are vital for
when standard periodontal therapy becomes a challenge
for both the patient (the ‘vulnerable category’ of patients
according to the mental health act), and the treating
dentist [www.cortexyme.com. https://www.cdc.gov/
chronicdisease/resources/publications/aag/alzhei
mers.htm]
Alzheimer’s disease (AD), the most common form
of dementia, is the leading cause of cognitive and
behavioural impairment worldwide [10]. As the
elderly population, keeps increasing so does the inci-
dence of AD manifesting in two different forms:
familial and sporadic. The latter form is most fre-
quent, constituting about 95% of the cases but its
cause remains open to debate. Both forms have iden-
tical neuropathological hallmarks, which are accumu-
lations of hyper-phosphorylated tau composed of
neurofibrillary tangles, and extracellular amyloid-
beta (Aβ) deposits called ‘amyloid plaques’. Tau pro-
tein is prone to hyper-phosphorylation at serine and
threonine residues due to the activity of multiple
CONTACT Sim K. Singhrao SKSinghrao@uclan.ac.uk Dementia and Neurodegenerative Diseases Research Group, Faculty of Clinical and
Biomedical Sciences, School of Dentistry, University of Central Lancashire, Preston, UK
JOURNAL OF ORAL MICROBIOLOGY
2019, VOL. 11, 1563405
https://doi.org/10.1080/20002297.2018.1563405
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
kinase enzymes orchestrating various signalling path-
ways for normal and key infection-related cellular
functions [11–13]. Managing AD is a financial and
medical challenge worldwide and prevention via
modifiable factors is one of the key ways to avoid
and/or decelerate progression of this disease [8,9].
Since the acceptance of any hypothesis explaining
the cause of AD must involve the two hallmark pro-
teins (Aβ and phosphorylated-tau tangles), and inter-
ventional studies in humans having tested beneficial
outcomes, we asked the question, how does sub-gin-
gival dysbiosis under the influence of P. gingivalis, the
keystone pathogen of periodontal disease, relate to
the cause of AD?
The main risk factors for the sporadic form of AD,
which correlates with chronic periodontitis, are
advancing age and loss of up to nine teeth [14].
Another study in which patients with chronic period-
ontitis and/or gingivitis, were monitored for 10 years
demonstrated an increased risk for dementia (1.13%)
compared with the control (0.92%) group [15]. While
periodontitis correlates with other inflammatory
pathologies such as cardiovascular diseases [16–18]
and diabetes [19], there is overlap of AD with
ischemic stroke disease [20] and insulin resistance
or as some scientists like to call it, type 3 diabetes
[21]. Periodontal disease is modifiable, and this pro-
vides the rationale for assessing causative associations
with AD. The focus here is on summarising key
epidemiological studies that have established the
timeline and size of risk, as well as research on in
vivo infection with P. gingivalis and its LPS support-
ing AD clinicopathological causal links and interven-
tional trials showing clinical benefits.
10-year exposure to chronic periodontitis
doubles the risk for AD
An epidemiological study by Kondo et al. [22] pro-
vided the initial concept, which proposed that persons
with premature tooth loss were a significant risk factor
for AD. Gatz et al. [23], investigated the risk of devel-
oping AD due to tooth loss in identical twins. For this
univariate human model, tooth loss around 35 years’
age provided an odds ratio of 1.74 (95% CI 1.35, 2.24)
for developing AD. Stein et al. [14] linked periodonti-
tis to cognitive deficit thereby proposing periodontal
disease as a risk factor for developing AD later in life.
They concluded that missing up to nine teeth carried
the highest risk for developing late-onset AD with an
odds ratio of 2.2 (95% CI 1.1, 4.5). A retrospective
study conducted by Chen et al. [24] found a strong
link between chronic periodontal disease (exposures of
around 10-years) and AD and this correlates with a
prospective laboratory-based study in which circulat-
ing antibodies to two oral bacteria (Fusobacterium
nucleatum and Prevotella intermedia) were linked to
a cognitive deficit 10 years later [25]. In summary,
Tzeng et al. [15], Chen et al. [24] and Sparks Stein et
al. [25] suggested that gingivitis, and chronic period-
ontal disease of 10 years duration can promote AD.
Furthermore, Stein et al. [14] showed tooth loss due to
periodontal disease can double the risk for AD onset.
Concept of systemic inflammation
contributing to memory loss
Dunn et al. [26] noted (from medical records), the
occurrence of repeated systemic infections in elderly
subjects prior to their clinical diagnosis of dementia.
This led to the assumption that inflammation plays a
negative role on the health of the brain. With focus on
peripheral inflammation, Holmes et al. [27] suggested
that circulating systemic inflammatory markers (cyto-
kines) were negatively influencing memory in sporadic
AD cases. Further studies examined the links with
specific periodontal pathogens to the functional cog-
nitive loss seen in clinical AD cases. To this end, Noble
et al. [28] found that P. gingivalis infection was asso-
ciated with impaired spatial/episodic memory in AD
with an odds ratio of 2.00 (95% CI 1.19 to 3.36) after
adjusting for confounders. Subsequent studies
focussed on detecting acute phase inflammatory med-
iators in the plasma of blood taken from confirmed
AD cases in relation to periodontal pathogens/period-
ontitis and confirmed systemic inflammatory marker
contribution from oral bacteria [29–31].
Ide et al. [31] set out to test the hypothesis that
circulating inflammatory cytokines due to periodontal
disease bacteria were associated with greater rates of
cognitive decline in clinical AD cases. The study
recruited 59 participants with mild to moderate AD in
which cognition and circulating inflammatory markers
were tested. The majority of participants (52) were fol-
lowed-up at 6 months when they all underwent repeat
assessment of their initial biomarkers. The study revealed
that the presence of periodontitis at baseline was asso-
ciated with a six-fold increase in the rate of cognitive
decline in participants over the 6-month follow-up per-
iod. Periodontitis at baseline was also associated with a
relative increase in the pro-inflammatory state over the
six-month follow-up. The authors concluded that peri-
odontitis is associated with an increase in cognitive
decline in AD. In this study, the scientific hypothesis
linking cognitive decline with the body’s inflammatory
responses was supported. The weaknesses of the study
were the small number of participants and absence of
control participants with intact cognition.
Host's microbiome dysbiosis is an important
environmental factor
A symbiotic oral microbiome plays a role in healthy
living and successful ageing [32,33]. However, a
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pathobiome prevails where pathogenic bacteria have
changed their original commensal status, as with P.
gingivalis-associated periodontal disease being a typical
example. A pathobiome in any part of a host’s body
represents an environmental risk factor. Although aber-
rant infections such as those linking Lyme disease
(Borrelia burgdorferi transmitted by a bite from infected
ticks, and syphilis (also known as an atrophic form of
general paresis caused by Treponema pallidum), even-
tually lead to AD [34,35], they represent a separate risk
factor to the so-called environmental risk that is
restricted to pathobiomes and lifestyle choices. This dis-
tinction is important in view of the apolipoprotein gene
allele 4 (APOE ε4) as a susceptibility gene that interacts
with environmental risk factors such as a sub-gingival
pathobiome that results in periodontal disease and/or
combined with smoking, poor choices of diet and a
sedentary lifestyle. This will likely enhance its biological
function in favour of AD. Hence, the current discussion,
where possible, is limited to P. gingivalis infections
because its interactome shows overlaps with AD suscept-
ibility genes making this bacterium an excellent candi-
date for confirming the environmental risk factor status
[2]. With the demonstration of P. gingivalis LPS exclu-
sively in AD brains, Poole et al. [36] have provided the
rationale for in vivo proof of concept studies.
The (simplified) amyloid cascade
The insoluble Aβ deposits (amyloid plaques) in the
AD brain [37] are the consequence of amyloid
precursor protein (APP) proteolysis along the N
terminus (start of the protein) to the cytoplasmic
tail at the C terminus (end of the amino acid chain
terminated by a free carboxyl group). The enzymes
generating Aβ are known as beta-secretase 1 or
BACE 1, which couples with γ-secretase in the
familial form of AD [38–40]. BACE 1 in this con-
text therefore, recognizes the cleavage site of the
mutated (mt)APP gene in the familial form of AD
and results in enhanced Aβ production [41]. This
genetic trait is the basis for generating transgenic
mouse models for evaluating human AD. However,
APP in the sporadic form of AD is not mutated
[42], and the results of infections can vary accord-
ing to the genetic make-up of the host animal. This
fact has to be considered by researchers when
selecting animal models to test their hypothesis
and by readers when comparing experimental out-
comes. Whilst, Aβ40 is the most prominent species
(80–90 %) found in AD brains, the amyloidogenic
Aβ42, overall represents the lesser component
(5–10 %) [37,43]. Other species of Aβ fibrils
(Aβ39, 38, 34, 33) also occur in the AD brain but
their presence is generally neglected [44] for rea-
sons poorly understood.
AD-transgenic mice support experimental
periodontitis as a nominal risk
Currently, there is only one report that employed the
APP-transgenic model (APP-Tg) carrying the Swedish
and Indiana mutations [45] infected with P. gingivalis
to assess the role of periodontitis in the development
of AD hallmark pathology (Table 1). After the lead
author’s communication with the senior author of
reference [45], the experimental regime was clarified
as the one in their published article was somewhat
misleading. It is therefore time to correctly state that
Ishida et al. [45], induced experimental periodontitis
via an oral, mono-infection with live P. gingivalis
ATCC 33277T. This is a seronegative strain commonly
used by global scientists in laboratory investigations.
The mice in this study were infected every other day
with 1 × 109 CFU over the first 10 days (five infec-
tions/10 days), and sacrificed five weeks after the first
infection. They noted enhanced deposition of Aβ40,
and Aβ42 amyloid plaques in the hippocampus and
higher levels of IL-1β and TNF-α in the infected APP-
Tg group compared to the control/sham-infected
group. Despite showing statistically significant differ-
ences in the Aβ40 and Aβ42 amyloid plaques (deter-
mined by image analysis) and protein (determined by
ELISA assay), Ishida et al. [45] concluded that five
mono-P. gingivalis infections over the first 10 days of
the experiment were likely to have exacerbated the
disease process rather than having contributed to the
overall Aβ hallmark pathology. Behavioural testing
demonstrated that the cognitive function was signifi-
cantly impaired in periodontitis-induced APP-Tg mice
compared to the sham-infected group. A mechanistic
explanation for the greater cognitive deficit in the
infected APP-Tg group was an increased intracerebral
inflammation following experimental periodontitis.
In vitro findings of Mueller-Steiner et al. [44] with
Aβ42 peptide incubation with cathepsin B (a lysosomal
enzyme that can mimic the enzymatic activity of BACE
1 in wild type APP), suggests that Aβ42 can be degraded
to Aβ40 and Aβ38. Taken together, the P. gingivalis-
infected APP-Tg group of the Ishida et al. [45] study
resulting in greater total Aβ load detected with their
82e1 antibody may have been the product of Aβ42
truncation. Therefore, Aβ oligomer distinction would
have been a better way to evaluate plaque data in the
infected group. Another weakness of this model was
that the method of entry of P. gingivalis into the mouse
brain remained unclarified. However, greater amounts
of LPS in the infected mouse brains were recorded
implying that this P. gingivalis virulence factor had
reached the brain and was responsible for stimulating
intracerebral antigen presenting cells (glia) to upregu-
late cytokine expression and liberation. However, func-
tional tests provide useful causal links with the AD
phenotype even in the familial form of AD.
JOURNAL OF ORAL MICROBIOLOGY 3
Mouse models with wild type APP support P.
gingivalis as a risk factor for AD
In contrast to the familial form of AD, the sporadic
form results mainly from the enzymatic processing of
the wild type (wt)APP. Cathepsin B coupled with the
common γ-secretase activity releases Aβ [42,46,47].
Both BACE 1 (mtAPP) and cathepsin B (wtAPP)
cleave at their specific amino acid motifs [46,48–51].
The insoluble Aβ amyloid plaques are unequivocally
extracellular, but it is not clear if their precursor
protein processing is extracellular or intracellular or
both. Hook et al. [46] hypothesized intracellular pro-
cessing of wtAPP via the regulated secretory vesicle
pathway mediated by cathepsin B and its exit from
the neuron (Figure 1). Unlike the mtAPP, that
implies extracellular processing by BACE 1 resulting
in enhanced Aβ, cathepsin B processing of wtAPP
appears to be intracellular yielding less Aβ.
Neuropathology diagnosis relies on a specific thresh-
old of Aβ amyloid plaques in both forms of AD; this
suggests that the sporadic form is a result of defective
clearance whilst the familial form results from
enhanced deposition of this insoluble protein
accounting for time differences in their early (famil-
ial) and late (sporadic) onsets. In this respect, the
Takayama et al. [52] study links P. gingivalis to
sleep disturbances and subversion of microglial cell
function, and paves the way for Aβ build-up.
P. gingivalis is an intracellular bacterium that
enters lysosomal bodies of cells following an endocy-
tic entry and the trans-Golgi network via the endo-
plasmic reticulum to avoid immune surveillance and
extend its viability [53]. Rather surprisingly, P. gingi-
valis and its LPS can manipulate endosomal/lysoso-
mal enzymes [54] to degrade wtAPP, intracellularly
(Figure 3), whilst IL-1β cytokine [55] provides the
inflammophilic sustenance (Figure 3). Since IL-1β is
part of the inflammasome assembly, P. gingivalis can
modify related activity in several ways [56]. Among
them are ATP/P2X7-signalling molecules, which are
associated not only with periodontitis but also with
the development of several systemic diseases [55,56].
Both TLR-2 and NLRP3 can recognize a functional
bacterial amyloid known as curli, within Aβ amyloid
plaques [57] and AD brain Aβ deposits transduce the
activation of the NLRP3 inflammasome in microglial
cells in vitro and in vivo [58–61].
Wild type mouse model of experimental
periodontitis supports neuroinflammation and
AD phenotype according to advancing age
Ding et al. [62] investigated periodontal disease effects
on the brain in C57BL/6J wild-type mice in four
(young) and 52-week (middle-aged) groups (Table 1).
Induction of experimental periodontitis was by an oralTa
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dose of live P. gingivalis (ATCC 33277T) mono-infec-
tion using 1 × 109 CFU, which was repeated every 48 h
over six weeks in each group. Evidence of intracerebral
inflammation was obtained by inflammatory cytokine
gene expression (using molecular biology methodolo-
gies), and protein release (using ELISA assay).
Cytokine levels (IL-1β, IL-6 and TNF-α) by both
methods were significantly higher in the P. gingivalis
mono-infected older age group. Ding et al. [62] also
performed behavioural tests and demonstrated statis-
tically significant outcomes for impaired spatial learn-
ing and memory in the older age (middle-aged,
52 week) group infected with P. gingivalis compared
to the younger (4-week old) and middle-aged unin-
fected mice. Increased intracerebral inflammation
accounted for the impaired spatial learning and mem-
ory following experimental periodontitis. The lack of
demonstration of P. gingivalis or its LPS entry into the
mouse brain alongside omission of observations
towards Aβ protein in the neuronal cell body is a
weakness of the study. This may imply that any
sequestered Aβ in the regulated secretory vesicle path-
way generated by cathepsin B processing was below
detection limits, provided the bacterium and or its LPS
entered the brain. However, functional tests provide
useful causal links with AD phenotype according to
advancing age, but imply that this is an inflammation-
mediated event secondary to infection.
Apolipoprotein E knockout mouse model of acute
and chronic periodontitis for AD neuropathology
The apolipoprotein E knockout (ApoE−/−) mouse har-
bours wtAPP in which periodontitis is induced follow-
ing an oral P. gingivalis mono-infection [63] (Table 1).
The mice received repeat infections (6 in 12 weeks’
duration and 12 in 24 weeks’ duration) with 1 × 109
CFU. The two time points corresponded to acute and
chronic periodontitis in mice. This model was the first
to evaluate migration, to the brain, of the same P.
Figure 1. The schematic suggests that the insoluble Aβ plaques are the result of intracellular processing of the wild type amyloid
precursor protein via the regulated secretory vesicle pathway mediated by cathepsin B (Taken from ref. 46 with permission).
Figure 2. The schematic representation suggests the role of peripheral inflammation that in this example is contributed by a period-
ontitis pocket infected by P. gingivalis. NF-κB signalling gives rise to cytokines and IL-1β and TNF-α appear to weaken the blood-brain
barrier (BBB) [65,66]. Bacteraemia allows P. gingivalis and its virulence factors to access the systemic circulation and enter the brain. P.
gingivalis and its virulence factors enter cells and pass along the endosome/lysosomes where they encounter cathepsin B [46,55].
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gingivalis strain used to infect the host orally at the 24-
weeks’ infection timeline, when the oral disease (peri-
odontitis) had become chronic [63,64]. Acute phase
inflammation in the form of the activated complement
system was detected at 24 weeks’ post infection with
evidence of neuronal vulnerability to necrotic cell
death [64]. At 12 weeks’ post infection, oxidative stress
and damage to the microvasculature in the hippocam-
pus were noted [65], but subsequent blood–brain bar-
rier (BBB) permeability in the cerebral (hippocampus)
cortex became apparent only after 24 weeks [66].
These findings support the chronic nature of period-
ontitis that subsequently converts to risk for AD as
highlighted by former prospective and retrospective
studies [24,25]. Poole et al. [64] and Rokad et al. [65]
endorsed the innate immune responses in the form of
complement activation and reactive oxygen species
(ROS)-mediated damage respectively, as described for
human AD [67]. Furthermore, BBB defects [66] linked
aging and AD protective barrier breakdowns [68–71].
The weaknesses of the ApoE−/− P. gingivalis-mono-
infection model are the inability to monitor insoluble
Aβ due to the total apolipoprotein gene knockout
because apolipoprotein E is one of the three essential
proteins required for amyloid fibril formation.
However, the positive outcomes of this study, in rela-
tion to the similarity between the sporadic form of AD
pathology and the ApoE−/− mouse model are many.
Firstly to proof of concept testing that P. gingivalis
following bacteraemia can translocate from its oral
niche to the brain [64]. Secondly, the peripheral
inflammation had a negative impact on the BBB integ-
rity [66]. Thirdly, P. gingivalis entry related directly to
the innate immune responses impacting on intracer-
ebral inflammation in the form of ROS, and comple-
ment activation [64,65]. These outcomes are
significant findings that outweigh the inability to assess
Aβ pathology in this periodontitis-AD model [63].
Wild type mouse model of periodontitis
demonstrates the cardinal AD lesions
The infection periodontal model of Ilievski et al. [72] is
C57BL/6 wild-type mice of 6 weeks’ age (Table 1). This
is the youngest cohort of animals tested in any of the
infection models thus far. Induction of experimental
periodontitis was by an oral dose of live P. gingivalis
(W83), serotype 1 encapsulated, bacterial mono-infec-
tion using 1 × 109 CFU, repeated every other day
(Monday-Friday) of every week for 22 weeks.
Evidence of intracerebral entry of the same P. gingivalis
(W83) used to infect the host orally at the 22-weeks’
infection timeline demonstrated its intracellular pre-
sence using fluorescent in-situ hybridisation or FISH
as used by Singhrao et al. [66]. FISH in the Ilievski et al.
[72] mice brain sections clearly demonstrates the sites
Figure 3. Illustrates the direct pathways by which P. gingivalis activity gives rise to the Alzheimer phenotype. Zhang et al. [74]
suggest this involves toll like receptor 4 (TLR-4) signalling) and Wu et al. [55] suggest microglial cytokine IL-1β for neuronal
function that bears its receptor on the membrane for intracellular processing of the amyloid precursor protein (APP) and
amyloid beta release as hypothesized by Hook et al. [46]. Ilievski et al. [72] demonstrated the build-up, in the mice brains, of
amyloid plaques outside the neurons and phosphorylation of tau on ser396 residue, an activity likely to be the result of the
glycogen synthase-3β (GSK-3β) enzyme. GSK-3β can be activated via the NF-κB signalling cascade or the increasing amyloid
plaque burden leading to neurofibrillary tangles (NFTs) forming. Inflammation following P. gingivalis entry into brain from an
oral niche is supported by Poole et al. [64] and subsequently by Ilievski et al. [72]. The encapsulated P. gingivalis W83 strain can
citrullinate structural proteins in glia and in neurons as described in reference [73].
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of infection in the various brain cells and in some cases
the nucleus. This clearly suggests the 22-week timeline
of their infection regime was somewhat excessive.
However, as a proof of concept study to determine
hallmark lesion formation, this is acceptable. Ilievski et
al. [72] detected inflammation by glial cell activation
supported by an elevated cytokine milieu within the
hippocampus. However, most interestingly, they
demonstrated the AD defining hallmark lesions. These
are amyloid plaques and de novo phosphorylated ser396
residue in tau protein that was bound to neurofibrillary
tangles within the hippocampus of the infected mice
group only. Although, this study lacked functional test-
ing in the presence of hallmark lesions in the hippo-
campus, it unequivocally demonstrated the causative
relationship of P. gingivalis with emerging AD pathol-
ogy, which in itself is a significant milestone.
P. gingivalis can citrullinate proteins
As the Ilievski et al. [72] study on infections favoured
P. gingivalis W83, which is a serotype 1 and capsu-
lated strain, it is important to mention that such a
strain has the capacity to produce citrullinated epi-
topes, which could be detrimental to the health of the
host [73]. Currently, there are no reports of P. gingi-
valis derived peptidyl arginine deiminase (PPAD)
activity in the brain possibly because these studies
are still novel and because antibodies to PPAD are
not widely available. In the future P. gingivalis W83
infections must examine this aspect of P. gingivalis
virulence to see if the disease follows an autoimmune
course or not.
P. gingivalis LPS and its effect on the brain
LPS is the major surface membrane component of
virulent Gram-negative bacteria such as P. gingivalis
(Figure 3). P. gingivalis LPS is an important contributor
to inflammation and neurodegeneration in AD because
pattern recognition receptors (PRRs), like Toll-like
receptors (TLRs), expressed by glia (as antigen present-
ing cells) can recognize pathogen-associated molecular
patterns (PAMPs) in microorganisms to trigger anti-
bacterial responses [45,55,62,64,74]. P. gingivalis LPS
can stimulate CD14, TLR-2 or −4 and send signals to
the nucleus by the MyD88 pathway, which initiates a
cascade of events that involve an increased expression
of proinflammatory cytokines [45,55,62,72,74]. This is
the background to the identification of the mechanism
of memory loss by the Zhang et al. [74] investigation
discussed below. Another noteworthy feature of P. gin-
givalis is that its LPS exists in at least two different
forms, O-LPS and A-LPS. The latter shows heterogene-
ity occurring as two isoforms, LPS1435/1449 and LPS1690
[75]. These isoforms can produce opposing effects on
TLR-2 and −4 activation. The capacity to change its LPS
to LPS1435/1449 or LPS1690 helps P. gingivalis in adjusting
to the local inflammatory milieu, enabling it to survive
in primary and distant sites, especially in lysosomal
compartments of different tissue cell types [54].
P. gingivalis-LPS model links with intracellular
Aβ in cathepsin B sufficient mice
Wu et al. [55] (Table 1) examined the effect of sys-
temic exposure to purified P. gingivalis-LPS (PgLPS)
in wild-type (C57BL/6N), young (2 months old) and
middle-aged (12 months old) mice and age-matched
cathepsin B sufficient and knockout mice for Aβ. The
experimental procedure involved intraperitoneal
injection of PgLPS from ATCC 33277T (1 mg/kg)
daily dose, for 5 weeks. The timespan for introduc-
tion of the endotoxin was determined from their
previous evaluation of systemic inflammation to
induce deficits in the hippocampal long-term poten-
tiation in middle-aged rats through microglia-
mediated neuroinflammation [76]. Inflammation
(activated astrocytes and microglia) and intracellular
Aβ in middle-aged cathepsin B sufficient mice were
reported together with learning and memory deficits.
An explanation for the neuronal Aβ and the memory
deficit included P. gingivalis using the endocytic/lyso-
somal pathway to enter cells and the consequence of
glial cell activation and cytokine release. P. gingivalis
LPS can mediate inflammation via cytokine (IL-1β)
release, and then generate intracellular Aβ by activa-
tion of cathepsin B in an age-dependent manner [55].
This study reported AD like behaviour following P.
gingivalis ATCC 33277T LPS introduction in mice,
and above all demonstrated intracellular release of
Aβ according to the hypothesis of Hook et al. [46]
via the regulated secretory vesicle pathway mediated
by cathepsin B (Figure 3), which consolidated the
causative relationships of P. gingivalis with AD [55].
This supports the Ilievski et al. [72] study linking
extracellular Aβ amyloid plaques following P. gingi-
valis infection in mouse models expressing wtAPP. In
addition, the Hook et al. [46] hypothesis suggested
the slower accumulation of extracellular amyloid pla-
ques in wtAPP protein. This distinction is very clear
from the Ilievski et al. [72] images, which show fewer
plaques compared with the images from the infected
APP-Tg group [45].
P. gingivalis LPS administration once in wild
type mice supports TLR-4 signalling leading
to AD phenotype
A study by Zhang et al. [74] aimed at dissecting out the
mechanism that leads to loss of memory following P.
gingivalis LPS intraperitoneal administration. The LPS
used here is the same as that administered in other
studies [55] confirming experimental consistency with
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previous phenotype related data outcome. The Zhang et
al. [74] study used 8-week-old C57BL/6 mice. A single
intraperitoneal injection of 5 mg/Kg P. gingivalis-LPS
was administered with/without the TLR-4 inhibitor
TAK-242. Seven days following the LPS and/or TLR-4-
inhibitor challenge, cognitive tests were performed,
which included the Open Field, Morris Water Maze
(MWM) and Passive Avoidance, Following sacrifice,
the brain tissues were examined for inflammatory mar-
kers by molecular biology, protein biochemistry and
immunohistochemistry. Compared with the control
group, Zhang et al. [74] found the test group receiving
P. gingivalis LPS had impaired spatial learning andmem-
ory during the MWM test and a weak desire for facing
fear in their ‘Passive Avoidance Test’. They also observed
glial (microglia and astrocytes) cell activation in the
cortex and the hippocampus regions of these mice brains
alongside of upregulated cytokines (TNF-α, IL-1β, IL-6
and IL-8). The TLR-4 inhibitor (TAK-242) group mice
brains demonstrated suppressed TLR-4/NF-κB signal-
ling pathways, and the same group of animals did not
show cognitive impairments. This confirmed the role of
TLR-4 signalling in poor memory development.
LPS links with tau protein phosphorylation in
AD transgenic mice
Bacterial products appear to play a detrimental role in
the onset and development of tau pathology.
Currently, there is only one report linking tau protein
phosphorylation due to P. gingivalis infection in mice.
In another study, the AD transgenic mouse model
(3xTg-AD and rTg4510) harbouring mutated tau
genes [11,13] has been administered with an intra-
peritoneal injection of purified commercial LPS from
Escherichia coli (12 doses over 6 weeks) in 4-months-
old 3xTg-AD mice; the authors firmly implicated the
role of microglial cytokines (IL-1β) in tau phosphor-
ylation [11]. These researchers also found increased
tau phosphorylation at Ser202/Thr205 and Thr231/
Ser235 residues in hippocampal neurons compared
with sham-infected transgenic control mice in kinase
specific activity [11]. What is intriguing is that Wu et
al. [55] have demonstrated a role for IL-1β in their
cathepsin B sufficient mice following introduction of
P. gingivalis LPS but without reporting tau phosphor-
ylation. This leaves gaps in our knowledge as to the
differing mechanisms of E. coli LPS and P. gingivalis
LPS [75] in initiating innate signalling cascades.
Lee et al. [13] injected commercial, purified LPS
from Salmonella abortus-equi (an aberrant infection
equivalent), demonstrating that phosphorylated tau
increases on select serine residues (Ser199/202 and
Ser396) in the mutated (rTg4510) group of mice
compared with controls. Differential tau phosphory-
lation at specific and plausible serine/threonine sites
is acceptable as it reflects the activity of specific
kinases that phosphorylate their respective amino
acid residues in the tau protein [11]. This suggests
that vulnerability in the tau gene, together with infec-
tions by Gram-negative bacteria, are able to influence
neurofibrillary tangle formation. However, AD does
not harbour mutations in the tau gene per se, and to
this end, Kitazawa et al. [11] observed that LPS
affected the phosphorylation of tau in the wild type
littermates over sham-infected non-transgenic mice,
which they attributed to inflammation. The results
confirm a causative role of bacterial LPS in the devel-
opment of the pathology in both the familial and
sporadic forms of AD with inflammation playing a
pivotal role in both APP processing and tau protein
phosphorylation at select residues.
Expression of AD phenotype in infected mice
Cognition describes a person’s mental ability to process
information, reasoning, and learning of new skills,
remembering them, and relating to them. Episodicmem-
ory, accounts for neuronal plasticity, whereby neurons
can modify the patterns of connectivity of functional
neurons through enhanced development of their den-
drites and axon elongation [77]. This ability appears to be
lost in AD and is the basis of the cognitive testing regime
designed to assess new patients for dementia. Synaptic
plasticity refers to the ability of synapses to modify to
adapt to challenges posed by ageing and disease pro-
cesses. These changes include size, morphology, density
and even complete loss of synapses within defined para-
meters of disease [78]. Spatial memory loss correlates
with synaptic loss [79] and earlier reports assigned Aβ
oligomer toxicity to synaptic loss in AD [80]. P. gingivalis
infection models described here are also displaying
impaired spatial and learning and memory deficits in
the younger and older age groups [55,62,74], and in the
AD transgenic and wild type infectedmouse models [45]
where inflammation is a common feature. Therefore,
inflammatory mediators such as IL-1β, which also has
detrimental effect on synapses, is a likely challenge from
infections that may correlate with plasticity and synapse
loss resulting in cognitive dysfunctional displays by
infected mice [45,55,62,74].
Interventional studies support periodontitis
as a risk factor for AD
The earliest interventional study was performed by
Rolim et al. [81], which included 29 participants with
clinically mild AD. A dentist performed a complete
evaluation involving: clinical questionnaire; research
diagnostic criteria for temporomandibular disorders;
McGill pain questionnaire; oral health impact profile;
decayed, missing and filled teeth index and complete
periodontal examination before and after the inter-
vention. The study found a reduction of orofacial
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pain, and improvement in the mandibular function
and periodontal indices in patients with AD. These
improvements were maintained until the last evalua-
tion after 6 months and were followed by a reduction
in the functional impairment due to cognitive com-
promise [81]. The limitation of this study is that it
lacked a bigger cohort and appropriate (non-AD)
controls.
Concluding remarks
P. gingivalis infections and its LPS appear to be clo-
sely associated with the development of the sporadic
form of AD. Data presented here are showing a con-
sistent causative role of P. gingivalis infections and its
LPS in mice for the development of cardinal hallmark
lesions and cognitive impairment via systemic and
intracerebral inflammation. In addition, inflamma-
tion is playing a pivotal role in APP processing to
generate Aβ, neurofibrillary tangle formation and
deteriorating memory. The time of onset (early vs
late) can be explained by modes of Aβ deposition.
For example, Aβ deposition in the familial AD brain
may arise directly by extracellular release from
mtAPP processing by BACE 1. However, wtAPP
appears to undergo intracellular processing and
release of Aβ mediated by the regulated secretory
vesicle pathway inflicted by cathepsin B processing
resulting in lesser yields. Neuropathology diagnosis
relies on a specific threshold of Aβ plaques in both
forms of AD; this may imply that the sporadic form
has a defective clearance while the familial form has
increased deposition of this insoluble protein. This
suggests that the 10-year lag phase of chronic period-
ontitis to become a risk factor for the sporadic form
of AD is plausible. Why the long lag phase? This may
be due to initial weakening of the protective BBB
through aging allowing easier access of bacteria into
the brain. Alternatively, unlike the oral cavity, which
embraces a range of diverse bacterial phylotypes and
develops chronic infection only after a few weeks, the
healthy brain may be slow to respond to nominally
virulent (seronegative) P. gingivalis stains in younger
human hosts because of their immune system. In
contrast, seropositive 1 strains such as W83 appear
to reach the brain with speed but the important
feature is the bacterial load. This goes back to poor
oral hygiene habits seen in patients.
Tau phosphorylation causal links with P. gingivalis
infection completes the intrigue that P. gingivalis can
initiate and produce both of the defining lesions of
AD. Ideally, functional tests on all related periodon-
titis infection for AD would be desirable but not
always possible, as the studies described here have
shown. In all instances, live P. gingivalis and its LPS
are powerful peripheral and intracerebral inflamma-
tory signalling initiators, and this has direct and early
implications on memory. The data presented here are
significant, contributing to our growing knowledge of
the causal associations between the sub-gingival
pathobiome under the influence of P. gingivalis and
development of AD. Maintaining an oral microbiome
symbiosis and preventing periodontal disease with
regular surveillance and good oral hygiene through-
out life is likely to reduce the incidence of unwanted
suffering from AD.
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